Sarepta Therapeutics (SRPT) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Zymeworks (ZYME) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 60.8% versus a loss of 24.3%. Over five years, ZYME leads with a +2.3% price change compared with -79.2% for SRPT. Zymeworks is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.
On valuation, Sarepta Therapeutics trades at a lower forward P/E (7.3x vs 30.4x for Zymeworks).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | ZYME |
|---|---|---|
| Share price | $17.50 | $26.53 |
| Market cap | $1.85B | $1.90B |
| 1-day change | +1.10% | +3.43% |
| YTD return | -18.68% | +0.76% |
| 1-year return | -24.31% | +60.79% |
| 5-year return | -79.21% | +2.27% |
| Forward P/E | 7.26 | 30.43 |
| EPS (TTM) | $-1.57 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.32 | $31.34 |
| 52-week low | $14.68 | $16.00 |
| Distance from 52-week high | -30.88% | -15.35% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.17% | +55.33% |
| Average volume | 2.99M | 673.06K |
| Shares outstanding | 105.63M | 71.20M |
| Employees | 835 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed SRPT by 85.1 percentage points over the past year.
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
SRPT vs ZYME FAQ
Which is bigger, Sarepta Therapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.90B compared with $1.85B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, SRPT or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.